Catalent Pharma Solutions, a global provider of drug delivery technologies and development solutions to the pharma industry, has hired William Haskins as Director of R&D, Bioanalytical Chemistry.
Reporting to David Rabuka, Catalent Biologics’ Global Head of R&D Chemical Biology, Haskins will join the team first formed by Redwood Bioscience, now part of Catalent Biologics, and will lead bioanalytical chemistry activities supporting Catalent’s proprietary SMARTag technology.
This technology is a precision protein-chemical engineering technology for the development of advanced antibody-drug conjugates (ADCs) and other therapeutic bioconjugates.
Haskins will be based at Catalent’s facility in Emeryville, CA, US.
He joins the firm from Genentech, where he led development and analytical characterisation of therapeutic ADCs, from late stage research to commercial.
Haskins has more than 23 years of basic and translational research experience, including drug and technical development leadership roles in Protein Analytical Chemistry at Genentech, seven years as a Director and Principal Investigator in the University of Texas system, with faculty appointments in Biology, Chemistry, Haematology and Oncology, and more than five years’ experience with major pharmaceutical, biotechnology and biomarker companies.
He holds a doctorate in bioanalytical chemistry from the University of Florida, a master’s degree in bioanalytical chemistry from Indiana University, and a bachelor’s degree in chemistry from New Mexico State University.
